TY - JOUR
T1 - Erythrocyte glutathione transferase activity
T2 - A possible early biomarker for blood toxicity in uremic diabetic patients
AU - Noce, Annalisa
AU - Fabrini, Raffaele
AU - Dessì, Mariarita
AU - Bocedi, Alessio
AU - Santini, Silvia
AU - Rovella, Valentina
AU - Pastore, Anna
AU - Tesauro, Manfredi
AU - Bernardini, Sergio
AU - Di Daniele, Nicola
AU - Ricci, Giorgio
PY - 2014
Y1 - 2014
N2 - Erythrocyte glutathione transferase (e-GST) displays increased activity in patients with renal damage and positive correlation with homocysteine (Hcy) in patients under maintenance hemodialysis. Here, we determined e-GST, Hcy, and erythrocyte catalase (e-CAT) in 328 patients affected by type 2 diabetes mellitus (T2DM), 61 diabetic non-nephropathic patients and 267 affected by diabetes and by chronic kidney disease (CKD) under conservative therapy subdivided into four stages according to K-DOQI lines. e-GST activity was significantly higher in all T2DM patients compared to the control group (7.90 ± 0.26 vs. 5.6 ± 0.4 U/gHb), and we observed an enhanced activity in all subgroups of CKD diabetic patients. No significant correlation or increase has been found for e-CAT in all patients tested. Mean Hcy in diabetic patients is higher than that in healthy subjects (33.42 ± 1.23 vs. 13.6 ± 0.8 μM), and Hcy increases in relation to the CKD stage. As expected, a significant correlation was found between e-GST and Hcy levels. These findings suggest that e-GST hyperactivity is not caused directly by diabetes but by its consequent renal damage. e-GST, as well as Hcy, may represent an early biomarker of renal failure.
AB - Erythrocyte glutathione transferase (e-GST) displays increased activity in patients with renal damage and positive correlation with homocysteine (Hcy) in patients under maintenance hemodialysis. Here, we determined e-GST, Hcy, and erythrocyte catalase (e-CAT) in 328 patients affected by type 2 diabetes mellitus (T2DM), 61 diabetic non-nephropathic patients and 267 affected by diabetes and by chronic kidney disease (CKD) under conservative therapy subdivided into four stages according to K-DOQI lines. e-GST activity was significantly higher in all T2DM patients compared to the control group (7.90 ± 0.26 vs. 5.6 ± 0.4 U/gHb), and we observed an enhanced activity in all subgroups of CKD diabetic patients. No significant correlation or increase has been found for e-CAT in all patients tested. Mean Hcy in diabetic patients is higher than that in healthy subjects (33.42 ± 1.23 vs. 13.6 ± 0.8 μM), and Hcy increases in relation to the CKD stage. As expected, a significant correlation was found between e-GST and Hcy levels. These findings suggest that e-GST hyperactivity is not caused directly by diabetes but by its consequent renal damage. e-GST, as well as Hcy, may represent an early biomarker of renal failure.
KW - Chronic kidney disease
KW - Diabetes
KW - Erythrocyte catalase
KW - Erythrocyte glutathione transferase
KW - Homocysteine
UR - http://www.scopus.com/inward/record.url?scp=84898411889&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84898411889&partnerID=8YFLogxK
U2 - 10.1007/s00592-013-0497-3
DO - 10.1007/s00592-013-0497-3
M3 - Article
C2 - 23818012
AN - SCOPUS:84898411889
VL - 51
SP - 219
EP - 224
JO - Acta Diabetologica
JF - Acta Diabetologica
SN - 0940-5429
IS - 2
ER -